Keeping up with CFTR modulator eligibility

Area of Science:

• Medical Science
• Pharmacology
• Genetics

Background:

• Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have revolutionized treatment for cystic fibrosis.
• Initial eligibility for CFTR modulators was based on clinical trial data for specific variants.

Purpose of the Study:

• To outline the evolving approaches for determining eligibility for CFTR modulators.
• To discuss strategies for improving prediction, verification, and monitoring of clinical response.
• To highlight the shift towards personalized medicine in cystic fibrosis care.

Main Methods:

• Review of regulatory approvals and evidence used for expanding CFTR modulator eligibility.
• Analysis of factors influencing variable clinical response to CFTR modulators.
• Discussion of advancements in in vitro 'theratyping' and real-world evidence utilization.

Main Results:

• CFTR modulator eligibility has expanded to over 180 variants beyond initial approvals.
• Regulatory bodies increasingly accept non-traditional evidence, such as cell-based assays.
• Clinical response to CFTR modulators is variable and influenced by multiple factors.

Conclusions:

• Personalized medicine approaches are crucial for optimizing CFTR modulator therapy.
• Continued research is needed to refine methods for predicting and monitoring treatment response.
• Advancements in evidence generation are broadening access to effective CFTR modulator therapies.